Improved Procedural Efficacy of Pulmonary Vein Isolation Using the Novel Second-Generation Cryoballoon

• Published in: Journal of cardiovascular electrophysiology 2013-05, Vol.24 (5), p.492-497
• Main Authors: FÜRNKRANZ, ALEXANDER, BORDIGNON, STEFANO, SCHMIDT, BORIS, GUNAWARDENE, MELANIE, SCHULTE-HAHN, BRITTA, URBAN, VERENA, BODE, FRANK, NOWAK, BERND, R. CHUN, JULIAN K.
• Format: Article
• Language: English
• Subjects: Aged; atrial fibrillation; Atrial Fibrillation - surgery; catheter ablation; Catheter Ablation - methods; cryoballoon; Cryosurgery - methods; Female; Humans; Male; Middle Aged; Operative Time; Postoperative Care; Postoperative Complications; pulmonary vein isolation; Pulmonary Veins - surgery
• ISSN: 1045-3873; 1540-8167
• DOI: 10.1111/jce.12082

Efficacy of the Novel Cryoballoon Introduction The cryoballoon technology has the potential to isolate a pulmonary vein (PV) with a single energy application. However, using the first‐generation cryoballoon (CB‐1G) repeated freezing or additional focal ablation is often necessary. The novel second‐generation cryoballoon (CB‐2G) features a widened zone of optimal cooling comprising the whole frontal hemisphere. The aim of this study was to investigate the impact of the novel design on procedural efficacy of cryoballoon PV isolation (CB‐PVI). Methods and Results Single transseptal CB‐PVI using an endoluminal spiral mapping catheter was performed in 60 consecutive patients (CB‐1G, 28 mm, 300 seconds application time: 30 patients; CB‐2G, 28 mm, 240 seconds application time: 30 patients). When compared to the CB‐1G, using the CB‐2G increased single‐shot PVI rate from 51% to 84% (P < 0.001) and decreased procedure duration (128 ± 27 vs 98 ± 30 minutes; P < 0.001), and fluoroscopy exposure time (19.5 ± 7.4 vs 13.4 ± 5.3 min; P = 0.001). Effective CB‐2G PVI could be performed with increased real‐time PVI visualization rate (49% vs 76%; P < 0.001). Time to PVI (TPVI) was shorter in the CB‐2G group (79 ± 60 vs. 52 ± 36 seconds; P = 0.049). Procedure‐related complications occurred in 2 patients in the CB‐1G group and 1 patient in the CB‐2G group. Conclusions The CB‐2G significantly improved procedural efficacy compared to the CB‐1G and provided reliable TPVI measurement. TPVI may be used to adjust application time and number individually in future studies. Final conclusions regarding the safety profile of the CB‐2G requires additional research.